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AHB and 769 AHC cases with 4,874 hepatitis A cases, used
as controls.
Results: For AHC, the strongest associations were with
urological [Adjusted Odd Ratio (ORadj,17.5; Cinﬁdence
Interval (CI), 1.6—187.1), neurological (ORad, 16.2, CI,
2.7—97.7), and minor surgery (ORad,10.9; CI,3.6—32.6). A
lower but signiﬁcant risk (from 3,7 to 4,7 times higher
respect to no intervention) was found for oral surgery,
Gynaecological, cardiovascular, abdominal interventions
and for biopsy or endoscopy. Only minor (ORad,3.0; CI,
1.3—7.1), oral (ORad, 2.6; CI,1.5—4.6) and dermatological
surgery (ORad, 2.9; CI, 1.1—7.5) were associated with AHB
instead, instead.
Conclusion: Although AHB and AHC incidences are declin-
ing, IP still represent important risk factors. The differences
in risk estimation between AHB and AHC is likely due to
the higher HCV prevalence in the general population; admit-
ting a person-to-person transmission by breaks in universal
precautions, the larger pool of subjects infected with HCV
than HBV makes more likely the exposure to HCV. The
increasing proportion of HBV-immunized young adults and
vaccination of high risk groups, further explain these differ-
ences. The high risk found for minor surgery, might suggest
that healthcare providers underrate the risk connected with
this procedure. Since a lot of people is exposed to IP
and an effective HCV vaccine is not yet available, these
ﬁndings underscore the importance of implementing non-
immunologic preventive measures to control iatrogenic HBV
and HCV transmission.
doi:10.1016/j.ijid.2008.05.1253
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Background: The ability to predict a favorable outcome of
treatment is a major issue in the management of hepatitis C.
Based on results of the viral kinetics studies, which indicated
a two-phase reduction in HCV RNA levels after IFN treatment
initiation, with the ﬁrst one appearing to be predictive of
response, we monitored the utility of the rapid virological
response (RVR), deﬁned as undetectable HCV RNA at week
4.
Methods: Samples from 38 patients (all females, mean
age 48,4± 5 ys) with chronic hepatitis C, but without signs
of cirrhosis, were tested for HCV viral load by quantitative
Rt- PCR (COBAS Amplicor HCV Monitor, Roche Diagnos-
tics) before initiation of treatment with PEG-IFN-alpha-2a
(180mcg/week) in combination with ribavirin (800mg/day)
for 48 weeks, at week 4 and at 6 month after the completion
of therapy. Genotyping was performed using a commercial
Line Probe Assay (Innogenetics).
Results: All patients had high baseline viral load
(>700 0000 IU/ml) and were infected with genotype 1b.
Despite these negative predictors for treatment success,
21 patients (75%) achieved a sustained virologic response
(SVR)- undetectable viral load at 6 month after discontinu-
ation of treatment. At week 4 after treatment initiation, 18
patients (64%) had undetectable viral load HCV. Out of these
rapid responders 17 (95%) achieved a SVR and only relapsed
at 6 month.By contrast, only 4 patients (36.4%) with HCV
RNA≥ 600 IU/ml at week-4 achieved an SVR.
Conclusion: The RVR may be a useful indicator for
the duration and long term outcome of treatment among
patients with chronic HCV infection, even in countries like
Romania, where genotype 1b is the most common. Lack of
RVR can justify discontinuation of therapy, with important
reduction in associated costs and adverse effects, while a
good response at week 4 indicates a low risk of relapses,
even in the presence of a less-sensitive genotype.
doi:10.1016/j.ijid.2008.05.1254
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Introduction: Hepatitis C virus (HCV) infection has
reached epidemic proportions. Worldwide, more than one
million new cases of infection are reported annually, and
HCV is believed to be more prevalent than hepatitis B virus
infection and 80% of the affected will be chronically infected
and are at risk of serious chronic sequel including cirrho-
sis and hepatocellolar carcinoma. Genotyping of HCV is
becoming increasingly important for clinical management of
chronic infection and as an epidemiological marker. At least
six major genotypes of HCV, each comprising multiple sub-
types, have been identiﬁed. Substantial regional differences
appear to exist in the distribution of genotypes. Although
HCV genotypes 1, 2, and 3 appear to have a worldwide distri-
bution, their relative prevalence varies from one geographic
area to another. subtypes 1a and 1b in the United States and
Europe, In Japan, subtype 1b, in northern Italy Subtype 2c,
Genotype 4 in North Africa and the Middle East, genotypes
5 and 6 in South Africa and Hong Kong are the most common
genotypes. Genotypes 7, 8, and 9 have been identiﬁed only
in Vietnamese patients, and genotypes 10 and 11 were iden-
tiﬁed in patients from Indonesia. We conducted this study to
detect the most common genotype in major thalassaemics
patients.
Methods and materials: We enrolled 52 patients of
HCV positive in a cross-sectional study. we used ELISA,
Restrictive-Fragment length polymorphism analysis and PCR
methods.
Result: 51.9% were men and 48.1% women. The mean
age (±SD) was 22± 4.48. Genotype 1a was the most com-
mon type (53%) after that 3a (42%) and 1b (5%).average of
viral load in patients with 1a genotype was 363501.1 and
in patients with 3a was 346621.3 that shows no signiﬁcant
difference.
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Conclusion: The most common genotype was 1a that it
was accordant to studies that conducted in general popula-
tion in Iran.
doi:10.1016/j.ijid.2008.05.1255
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Background: Chronic infection of hepatitis C virus (HCV)
may lead to hepatic ﬁbrosis and the precise mechanisms
remain unclear. Our previous study indicated that E2 protein
may involve in the hepatic ﬁbrogenesis via an up-regulation
of ﬁbrosis-related proteins.
Methods: To further conﬁrm this ﬁnding, E2 gene silenc-
ing and a treatment with silibinin was conducted on
E2-expressing cells and RT-PCR analysis was performed.
Results: E2-enhanced expression of ﬁbrosis-related
molecules, including alpha-SMA, collagen alpha(I), TGF-1,
connective tissue growth factor (CTGF), IL-6 and IL-1, MMP-
2, were all abolished by a treatment with siRNA speciﬁc
for E2. Furthermore, a treatment with silibinin, a potent
antioxidant, was conducted to gain similar results.
Conclusion: These results further prove that E2 protein
may involve in the process of hepatic ﬁbrogenesis and E2-
related ﬁbrosis may be, at least in part, through an oxidative
damage-related pathway.
doi:10.1016/j.ijid.2008.05.1256
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Introduction: Impaired natural killer (NK) cell activity
contributes to viral persistence in HCV infection. Recent
studies demonstrated that in tumors regulatory T cells (Treg)
- via secreting TGF-beta1 - down-regulate NKG2D killer
activator receptor and are responsible for poor NK cytox-
icity. Since in chronic hepatitis C plasma TGF-beta1 level is
increased, we analyzed the expression of NKG2D on NK and
T cells and its correlation with the percentage of Treg cells
and TGF-beta1 levels.
Methods: The peripheral CD4+CD25high+ Treg cells,
NKG2D+ NK and T cells were determined by FACS, plasma
TGF-beta1 levels by ELISA. Forty three patients with active
chronic hepatitis C, 10 sustained virological responders
(SVR) and 15 healthy controls were enrolled.
Results: In patients with chronic hepatitis C the NKG2D
expression was down-regulated both on NK (7,9 vs. 20,9%)
and T cells (18 vs. 26,3%) compared to controls. Impaired
expression of NKG2D was associated with increased pro-
portion of CD4+CD25high+ Treg cells (4,6 vs. 3,1%) and
increased TGF-beta1 levels (15 vs.9 pg/ml) compared to con-
trols. TGF-beta1 inversely correlated with NKG2D expression
on NK cells. In SVR group, the percentage of Treg cells
(1,7± 0,2%), TGF-beta1 levels (11,6 pg/ml) and NKG2D
expression (NK:17%, T:20,9%) were comparable to controls.
Discussion/Conclusion: Our data suggest that TGF-beta1
- secreted by regulatory T cells - may be responsible for
impaired NK cell function via down-regulating NKG2D. Thus,
TGF-beta1 antagonism or soluble NKG2D ligands may provide
the basis of a novel immunotherapy to improve the function
of NK and T cells in chronic hepatitis C.
doi:10.1016/j.ijid.2008.05.1257
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Objective: A nation-wide retrospective analysis has been
performed in order to assess the efﬁcacy of antiviral therapy
for patients with chronic hepatitis B and C representing the
entire population that needed treatment in Hungary, during
a seven-year period. In addition, results of a prospective
study including patients with chronic hepatitis C are also
presented.
Patients and Methods: Of 220 patients with hepatitis
B, 112 were treated with standard interferon-alpha (IFN),
23 with pegylated interferon-alpha-2a (PEG-IFN) and 85
with lamivudine (LAM), and the ratio of HBeAg seroconver-
sion and/or undetectable HBV-DNA has been assessed. Of
2442 patients with hepatitis C, 333 were treated with IFN
monotherapy, 1122 with IFN + ribavirin (RBV) and 987 with
PEG-IFN + RBV for 6—12 months. In the prospective study, 69
patients with chronic hepatitis C were enrolled and treated
with PEG-IFN alfa-2a + RBV. The rate of sustained virological
response (SV), the predictors of outcome and the adverse
effects of treatment were evaluated.
Results: For HBV patients IFN, PEG-IFN and LAM provided
31, 30, and 33% SVR rate, respectively. In chronic hepatitis C,
